Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$1.58 -6.0%	$2.10	$1.55 ▼ $17.31	$38.49M	N/A	170,906 shs	420,073 shs
AVTX Avalo Therapeutics	$4.64 -2.5%	$4.42	$3.39 ▼ $16.00	$50.25M	0.7	59,209 shs	33,833 shs
BCTX Briacell Therap	$3.06 -1.9%	$3.68	$2.81 ▼ $29.40	$20.75M	1.31	551,272 shs	62,662 shs
ZIVO ZIVO Bioscience	$14.22	$16.26	$5.53 ▼ $22.15	$54.22M	0.02	989 shs	214 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	-20.20%	-18.97%	-59.59%	+157,999,900.00%
AVTX Avalo Therapeutics	0.00%	-4.13%	+23.73%	-39.19%	-64.42%
BCTX Briacell Therap	0.00%	-1.92%	-0.33%	-31.39%	-82.93%
ZIVO ZIVO Bioscience	0.00%	+1.64%	-21.00%	-21.00%	+74.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	2.5773 of 5 stars	3.5	0.0	2.0	1.7	1.3
AVTX Avalo Therapeutics	3.4558 of 5 stars	3.5	5.0	2.2	1.7	1.3
BCTX Briacell Therap	2.4977 of 5 stars	3.5	2.0	4.4	0.0	0.6
ZIVO ZIVO Bioscience	0.0735 of 5 stars	0.0	2.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$17.80	1,026.58% Upside
AVTX Avalo Therapeutics	3.00	Buy	$30.00	546.55% Upside
BCTX Briacell Therap	3.00	Buy	$32.00	945.75% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BCTX, ARTV, AVTX, and ZIVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/15/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $18.00
4/22/2025	BCTX Briacell Therap	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/8/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/26/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00 ➝ $18.00
3/25/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/25/2025	AVTX Avalo Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform ➝ Buy	$23.00
3/25/2025	AVTX Avalo Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	153.96	N/A	N/A	$7.68 per share	0.21
AVTX Avalo Therapeutics	$440K	114.21	N/A	N/A	$12.80 per share	0.36
BCTX Briacell Therap	N/A	N/A	N/A	N/A	($2.20) per share	N/A
ZIVO ZIVO Bioscience	$15.85K	3,420.87	N/A	N/A	($0.81) per share	-17.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-75.95%	-39.51%	6/23/2025 (Estimated)
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	111.00%	58.88%	8/11/2025 (Estimated)
BCTX Briacell Therap	-$4.79M	-$8.32	N/A	N/A	N/A	N/A	-479.97%	-182.26%	N/A
ZIVO ZIVO Bioscience	-$7.78M	-$4.93	N/A	∞	N/A	N/A	N/A	-2,240.92%	8/12/2025 (Estimated)

Latest BCTX, ARTV, AVTX, and ZIVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/13/2025	Q3 2025	BCTX Briacell Therap	-$1.76	-$1.64	+$0.12	-$1.64	N/A	N/A
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
5/8/2025	Q1 2025	ARTV Artiva Biotherapeutics	-$0.68	-$0.83	-$0.15	-$0.83	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	13.93	13.93
AVTX Avalo Therapeutics	N/A	22.61	22.61
BCTX Briacell Therap	N/A	3.41	3.41
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
AVTX Avalo Therapeutics	87.06%
BCTX Briacell Therap	15.42%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
AVTX Avalo Therapeutics	0.25%
BCTX Briacell Therap	5.73%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.36 million	19.15 million	N/A
AVTX Avalo Therapeutics	40	10.83 million	10.80 million	Not Optionable
BCTX Briacell Therap	8	6.78 million	6.39 million	Optionable
ZIVO ZIVO Bioscience	10	3.81 million	2.91 million	Not Optionable

BCTX, ARTV, AVTX, and ZIVO Headlines

Recent News About These Companies

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20 at 8:00 AM | businesswire.com

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Passes Below 50 Day Moving Average - Here's What Happened

June 17, 2025 | marketbeat.com

ZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Above 50-Day Moving Average - Time to Sell?

June 7, 2025 | marketbeat.com

ZIVO Bioscience (NASDAQ:ZIVO) Shares Cross Below 50-Day Moving Average - Should You Sell?

May 30, 2025 | marketbeat.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.com

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.com

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 2, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.com

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX, ARTV, AVTX, and ZIVO Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$1.58 -0.10 (-5.95%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.63 +0.05 (+3.16%)

As of 06/20/2025 07:43 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Avalo Therapeutics NASDAQ:AVTX

$4.64 -0.12 (-2.52%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.64 0.00 (-0.11%)

As of 07:26 AM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Briacell Therap NASDAQ:BCTX

$3.06 -0.06 (-1.92%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.03 -0.03 (-0.98%)

As of 07:26 AM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

ZIVO Bioscience NASDAQ:ZIVO

$14.22 0.00 (0.00%)

As of 06/20/2025

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time